- Life Sciences
- Conference
Tumor Models Boston Summit 2024
Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare. We are pleased to share more information about our platform of 3D patient-derived organoids (PDOs), as well as how leveraging Tempus PDOs can help address common pain points in pre-clinical cancer research and drug development.
Lab-in-the-loop: Leveraging Tumor Organoids and RWD to Generate Multimodal Insights for Drug Development
High failure rates and increased costs in drug development are driven by lack of robust preclinical models in the discovery and translational space. Tempus has built a platform of 3D patient-derived organoids (PDOs) grounded in de-identified real-world clinical data to address this gap. With one of the largest, pan-indication patient-derived organoid repositories in the industry, Tempus' portfolio of fixed screening panels supports research questions across a range of modalities including small molecules, antibody drug conjugates, and cell therapies.
Michelle Mack Senior Director, Business Development, Biological Modeling (Tempus)
Learn more↗Schedule a meeting with us
We'll be in touch shortly.